Hodder S, et al. - The efficacy, safety, and tolerability of switching to a tenofovir alafenamide (TAF)-based, single-tablet regimen containing elvitegravir, cobicistat, FTC, and TAF (E/C/F/TAF) vs remaining on ritonavir-boosted atazanavir (ATV + RTV) plus FTC/TDF were investigated in virologically suppressed (HIV-1 RNA <50 copies/mL) women. Findings revealed noninferiority of switching to E/C/F/TAF to continuing ATV + RTV plus FTC/TDF in maintaining virologic suppression and was well tolerated at 48 weeks. The groups demonstrated similar incidence of AEs; study drug related AEs were more common with E/C/F/TAF.